Market capitalization | $55.48m |
Enterprise Value | $156.77m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 13.43 |
EV/Sales (TTM) EV/Sales | 2.84 |
P/S ratio (TTM) P/S ratio | 1.01 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 65.72% |
Revenue (TTM) Revenue | $55.15m |
As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.
4 Analysts have issued a Scilex forecast:
4 Analysts have issued a Scilex forecast:
Sep '24 |
+/-
%
|
||
Revenue | 55 55 |
66%
66%
|
|
Gross Profit | 35 35 |
54%
54%
|
|
EBITDA | -79 -79 |
-
|
EBIT (Operating Income) EBIT | -83 -83 |
45%
45%
|
Net Profit | -88 -88 |
25%
25%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Jaisim Shah |
Employees | 105 |
Founded | 2020 |
Website | www.scilexholding.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.